Abiraterone with discontinuation of gonadotropin-releasing hormone (GnRH) analogues in patients (pts) with metastatic prostate cancer (PC): Survival results from a single-arm, phase II study.
Authors: Dimitrios Makrakis, Matan Uriel, Sanjay Goel, Charles B. Hall, Darciann O'Sullivan, Christopher D. Jakubowski, Monique White, Benjamin Gartrell